AAIPharma Services/Cambridge Major Laboratories expands Disinfectant Effectiveness/Qualification Services
Now has two sites in the US offering these services
AAIPharma Services/Cambridge Major Laboratories (AAI/CML) has expanded its service to offer two sites for Disinfectant Effectiveness/Disinfectant Qualification (DE/DQ) studies.
AAI/CML now offers DE/DQ at its St. Louis, MO facility, which complements existing services at Edison, NJ, to meet high customer demand and provide regional support. These studies meet USP <1072> Disinfectants and Antiseptics and help customers to comply with cGMP 21 CFR 211.67, Equipment Cleaning and Maintenance.
The expansion allows AAI/CML to further support sterile and non-sterile product manufacturers in the development and qualification of disinfectant programmes to prevent microbial contamination through pharmaceutical ingredients, process water, packaging components, manufacturing environment, and process and manufacturing equipment.
'This added capability allows us to offer more options for regional proximity and flexibility for manufacturing and testing with AAI/CML from both our St. Louis, MO and Edison, NJ sites,' said Ted Dolan, Chief Operating Officer.
AAIPharma Services and Cambridge Major Laboratories merged to become a supplier of comprehensive pharmaceutical development and manufacturing services. With seven sites across the globe, the combined capabilities include API development and manufacturing, solid state chemistry, formulation development, analytical development and testing services, clinical and commercial finished dosage form manufacturing (solid dose and parenteral), packaging, and stability services. The family of companies is in the portfolio of American Capital.
